# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ann Richards (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML019-SYN-TD
- Date: 1997-02-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rosalind Teague, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for new patient visit for bone health after a fall with a hand fracture. **S**

## Objective

Lumbar spine (L1-L4) T-score: -2.3 (low); Femoral neck T-score: -2 (low); Total hip T-score: -1.7 (low); FRAX 10-year major osteoporotic fracture risk: 22%; FRAX 10-year hip fracture risk: 3.6%; Calcium: 9.4 mg/dL; Albumin: 4.2 g/dL; Creatinine: 0.8 mg/dL; eGFR: 81 mL/min/1.73 m²; Phosphate: 3.5 mg/dL; Magnesium: 2 mg/dL; Alkaline phosphatase: 84 U/L; PTH: 54 pg/mL; TSH: 1.9 mIU/L; Hemoglobin: 13.3 g/dL; ALT: 21 U/L; 25-hydroxyvitamin D: 24 ng/mL (low); Serum CTX (fasting morning sample): 560 pg/mL; PHQ-9: 2; AUDIT-C: 0. All results are synthetic.

BP 124/76 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 66 kg; BMI 24.5 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Low bone mass (osteopenia) of the lumbar spine and hip on DXA, lowest T-score -2.3 at the lumbar spine (femoral neck -2.0, total hip -1.7), with a 10-year FRAX risk above the treatment thresholds (major osteoporotic fracture 22 percent, hip 3.6 percent); not osteoporosis by T-score, but meets the AACE 1991 clinical criteria for osteoporosis (low bone mass with a FRAX risk above threshold); Alcohol use disorder in sustained remission for more than fifteen years, since treatment; no alcohol since; History of falls: a fall from standing height with a hand fracture last year (and, in one account, a second fall with an ankle fracture); no falls since. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Started: Cholecalciferol (vitamin D3) 50 mcg (1971 units) oral tablet, one tablet daily **S**

## Plan

- Endocrinology consultation to confirm the diagnostic category from the T-scores and FRAX, the risk category, the choice of drug, the secondary-causes work-up, and the plan for monitoring and treatment duration. Guideline: CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); The clinician's guide to prevention and treatment of osteoporosis (2022); American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis, 2020 Update (2020); Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline (2019) **S**
- Calcium about 1200 mg a day in total, from food first, and vitamin D3 1971 units a day to reach 30 ng/mL or more, then continue; caffeine kept to two cups of coffee a day; no tobacco or alcohol. Guideline: CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); The clinician's guide to prevention and treatment of osteoporosis (2022); American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis, 2020 Update (2020) **S**
- Falls prevention by CDC STEADI: supervised balance and strength exercise with a physical therapist for eight weeks, then a home program three times a week; weight-bearing exercise most days; home safety review (stair rails, night lights, no loose rugs); low-heeled shoes when traveling; yearly vision check. Guideline: The clinician's guide to prevention and treatment of osteoporosis (2022); Falls Prevention in Community-Dwelling Older Adults: Interventions (2024); STEADI: Stopping Elderly Accidents, Deaths, and Injuries (2026) **S**
- Monitoring on the CMID osteoporosis schedule: secondary-causes tests at baseline (calcium, albumin, phosphate, magnesium, alkaline phosphatase, creatinine and eGFR, PTH, 25-hydroxyvitamin D, TSH, blood count, and 24-hour urine calcium); calcium and creatinine before each infusion; fasting CTX at baseline and three to six months after starting; 25-hydroxyvitamin D after repletion and then yearly; height and fall-risk screen yearly; FRAX recalculated when risk factors change; DXA of the spine and hip two years after starting, on the same scanner. Guideline: CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis, 2020 Update (2020); Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline (2019); Osteoporosis to Prevent Fractures: Screening (2025) **S**
- Recovery-oriented care for alcohol use disorder in sustained remission: ask about alcohol, cravings, and stress at each visit in a non-judgmental way, support the recovery practices she uses, avoid sedating medicines, and review safety with the 988 Suicide & Crisis Lifeline at each visit. Guideline: CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024) **S**
